TICKERNERD
Menu
ABEOABEOHealthcare · Biotechnology

ABEO Stock Forecast: Abeona Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$6.10
+2.31% on the day

The 6 Wall Street analysts covering Abeona Therapeutics, Inc. hold a median 12-month price target of $17 — +178.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$348.3M
Ticker Nerd rank
42 / 100
Median analyst target
$17
Analysts covering
6
Total return, dividends reinvested
1W
+1.8%
1M
−6.6%
YTD
+15.7%
1Y
−14.2%
From 52W high
−18.3%
From 52W low
+46.2%
$4.17
$7.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABEO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Abeona Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
68
Volatility
63
Size
59
Growth
56
Issuance
55
Value
48
Revisions
37
Momentum
33
Accruals
32

Quality (68): The business earns solid, repeatable profits on what it owns.

Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABEO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABEO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26ABEOHigh $28Median $17Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $14Median $17High $28

The green dot is the last close — the median target sits +178.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026OppenheimerMaintainsOutperform$22 → $21
28 May 2026HC Wainwright & Co.ReiteratesBuy$20
28 May 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
13 Oct 2025HC Wainwright & Co.ReiteratesBuy—
18 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
16 July 2025HC Wainwright & Co.ReiteratesBuy—
14 July 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025OppenheimerAssumesOutperform$19
16 May 2025StifelMaintainsBuy—
30 Apr 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Mar 2025OppenheimerInitiatesOutperform—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
29 Oct 2024Cantor FitzgeraldReiteratesOverweight—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight$18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABEO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ABEO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Abeona Therapeutics, Inc. (ABEO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.8×

Cheaper than 62% of US stocks

Price / sales
13.6×

Cheaper than 12% of US stocks

Price / book
2.7×

Cheaper than 37% of US stocks

EV / EBITDA
−2.7×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
2745.0%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
69.1%

Higher than 82% of US stocks

Operating margin
−120.0%

Higher than 13% of US stocks

Net margin
−246.4%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−43.1%

Higher than 23% of US stocks

Return on assets
−24.6%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ABEO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABEOAbeona Therapeutics, Inc.$348.3M
42
STROSutro Biopharma, Inc.$344.8M
75
SABSSAB Biotherapeutics, Inc.$343.9M
36
DMACDiaMedica Therapeutics, Inc.$351.6M
48
IMRXImmuneering Corp.$342.2M
46
CAPRCapricor Therapeutics, Inc.$361.7M
13
IKTInhibikase Therapeutics, Inc.$333.5M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Abeona Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABEO news & analysis

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity

Seeking Alpha · 13 Aug 2026negative

Abeona Therapeutics reported Q2 revenues of $11.4m and treated five Zevaskyn patients, but missed analyst expectations, causing a 14% stock decline. The company faced operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, while management expects improvement with experience and cited partnered programs with Ultragenyx and Taysha as potential catalysts.

Why it matters — ABEO watchers would care because the earnings miss and rollout difficulties highlight near-term execution risks, while partnered programs and expected operational improvements could shape the stock's direction.

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Abeona Therapeutics held its second-quarter 2026 earnings call, and Seeking Alpha published a transcript of the proceedings. The item indicates the company reported on its Q2 2026 financial results and provided related discussion during the call.

Why it matters — ABEO watchers would rely on the transcript for the company's latest quarterly financial results and management commentary.

Abeona Therapeutics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Abeona Therapeutics reported second-quarter revenue growth from its ZEVASKYN cell therapy launch, while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.

Why it matters — Abeona watchers would care because the report shows early commercial momentum for ZEVASKYN alongside operational hurdles that could affect future revenue recognition.

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

GlobeNewsWire · 13 Aug 2026positive

Abeona Therapeutics reported second quarter 2026 financial results, with net ZEVASKYN revenue increasing 31% quarter-over-quarter to $11.4 million. Five patients were treated in Q2 2026 and three in Q3 2026 to date, bringing total treatments to 12 since launch, while the treatment network expanded to seven sites and cash stood at $146.8 million as of June 30, 2026.

Why it matters — The quarterly results show sustained growth in ZEVASKYN commercialization, with rising revenue, an expanding treatment network, and a solid cash position that ABEO watchers would track for the product's launch trajectory.

FAQ

Frequently asked questions about ABEO stock

What is the ABEO stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Abeona Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $14 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABEO stock a buy right now?

Of the 6 analysts covering Abeona Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abeona Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABEO?

As at 22 Aug 2026, Abeona Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (68 of 100).

Will ABEO stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +178.8% from the last close, and Ticker Nerd's factor model ranks Abeona Therapeutics, Inc. 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABEO stock forecast for 2030?

No analyst covering Abeona Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $28 over the next 12 months.

How has ABEO stock performed over the past year?

Abeona Therapeutics, Inc. returned -14.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Abeona Therapeutics, Inc. do?

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic and rare diseases.

What is the latest news on ABEO?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity". Abeona Therapeutics reported Q2 revenues of $11.4m and treated five Zevaskyn patients, but missed analyst expectations, causing a 14% stock decline. The company faced operational setbacks in Zevaskyn's rollout, including cancellations and manufacturing issues, while management expects improvement with experience and cited partnered programs with Ultragenyx and Taysha as potential catalysts.

Company

About Abeona Therapeutics, Inc.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic and rare diseases. Headquartered in Cleveland, Ohio, and founded in 1974, the company concentrates on advanced platforms such as adeno-associated virus (AAV) gene therapies and cell-based approaches targeting conditions with high unmet medical need. Abeona Therapeutics’ pipeline is oriented toward disorders where durable treatment effects from a single administration could transform patient outcomes, particularly in inherited metabolic and connective tissue diseases. Its work spans research, clinical development, and regulatory interactions to bring novel therapies through late-stage trials. Within the healthcare technology and pharmaceutical sectors, Abeona Therapeutics plays a specialized role at the intersection of gene therapy innovation and rare disease medicine, collaborating with academic centers, clinical investigators, and industry partners to advance its therapeutic candidates and support broader adoption of gene-based treatments in modern medicine.

CEO Dr. Vishwas Seshadri M.B.A., Ph.D. · 226 employees · United States · https://www.abeonatherapeutics.com